(Q43545515)

24 November 2017

title

Fenofibrate raises plasma homocysteine levels in the fasted and fed states. (English)

1 reference

24 November 2017

Bissonnette R

1

1 reference

24 November 2017

Treacy E

2

1 reference

24 November 2017

Rozen R

3

1 reference

24 November 2017

Boucher B

4

1 reference

24 November 2017

Cohn JS

5

1 reference

24 November 2017

Genest J Jr

6

1 reference

24 November 2017

publication date

1 April 2001

1 reference

24 November 2017

1 reference

24 November 2017

volume

155

1 reference

24 November 2017

issue

2

1 reference

24 November 2017

page(s)

455-462

1 reference

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Epidemiologic aspects of lipid abnormalities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Systematic review on the risk and benefit of different cholesterol-lowering interventions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Measurement of homocyst(e)ine in the prediction of arteriosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Correlation of a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Postprandial lipemia, fenofibrate and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Lipid-lowering drugs and homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Lipid-lowering drugs and homocysteine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Homocysteine and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Homocysteine and coronary atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Plasma homocysteine levels and mortality in patients with coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Homocyst(e)ine: an important risk factor for atherosclerotic vascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Diabetes and atherosclerosis--a lipoprotein perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Diabetes, hyperlipidemia, and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

Effects of age, lipoproteins, and hemostatic parameters on the role of homocyst(e)inemia as a cardiovascular risk factor in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2800%2900584-0

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0021-9150(00)00584-0

1 reference

24 November 2017

1 reference